skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
Emulsion-based adjuvants for influenza vaccines
Expert review of vaccines, 2009-04, Vol.8 (4), p.483-492
[Peer Reviewed Journal]
Expert Reviews Ltd 2009 ;2009 © Expert Reviews Ltd ;ISSN: 1476-0584 ;EISSN: 1744-8395 ;DOI: 10.1586/erv.09.5 ;PMID: 19348563
Full text available
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Emulsion-based adjuvants for influenza vaccines
Author:
Vogel, Frederick R
;
Caillet, Catherine
;
Kusters, Inca C
;
Haensler, Jean
Subjects:
adjuvant
;
Adjuvants
;
Adjuvants, Immunologic - administration & dosage
;
Adjuvants, Immunologic - pharmacology
;
AF03
;
AS03
;
Clinical trials
;
Clinical Trials as Topic
;
emulsion
;
Emulsions - administration & dosage
;
Emulsions - pharmacology
;
Epizootics
;
Europe
;
Exo- alpha -sialidase
;
Geriatrics
;
Hemagglutinins
;
Humans
;
Immunogenicity
;
incomplete Freund's adjuvant
;
influenza
;
Influenza A
;
Influenza A virus
;
Influenza A virus - immunology
;
Influenza A Virus, H5N1 Subtype - immunology
;
Influenza Vaccines - immunology
;
Influenza virus
;
MF59
;
pandemic
;
pandemics
;
Pathogenicity
;
Reviews
;
vaccine
;
Vaccines
Is Part Of:
Expert review of vaccines, 2009-04, Vol.8 (4), p.483-492
Description:
The ongoing epizootic of highly pathogenic avian H5N1 influenza and its direct transmissibility and high pathogenicity in humans has led to renewed interest in the development of influenza vaccines with enhanced immunogenicity. Influenza vaccines are currently under development against influenza strains that are potentially pandemic threats, such as H5N1, as well as against the current seasonal influenza strains for use in populations susceptible to severe influenza disease. Influenza vaccines may be generally divided into two types: seasonal vaccines for use in a population that is largely primed to subtypes of the circulating influenza A strains and pandemic influenza vaccines that are designed to protect against influenza A viruses of a hemagglutinin (HA) subtype, to which the vast majority of the population is immunologically naive. Pandemic influenza vaccines can be further subdivided into prepandemic vaccines produced for use prior to or just after the declaration of a pandemic, and pandemic influenza vaccines that would be produced and used only after a pandemic is declared. Prepandemic influenza vaccines are formulated using HA and neuraminidase, which are likely to be antigenically similar to the influenza virus subtype deemed to pose the most probable pandemic threat. Enhanced vaccine immunogenicity is desirable for pandemic influenza vaccines and for seasonal vaccines used in target populations, such as the elderly, in which vaccine responses against the circulating influenza subtypes may be weak. Various methods to enhance the immunogenicity of influenza vaccines are under evaluation. Along with dose escalation and alternative delivery routes, strategies for improving the immunogenicity of influenza vaccines have focused on the use of immunologic adjuvants. An adjuvanted seasonal influenza vaccine, FluadĀ®, has been licensed in some countries in Europe since 1997 for the elderly population, and a number of clinical trials have been completed or are in progress evaluating the use of adjuvants with pandemic and seasonal influenza vaccines. This review will focus on the use of emulsion-based adjuvants for enhancing the immunogenicity of pandemic influenza vaccines and of seasonal influenza vaccines in target populations.
Publisher:
England: Informa Healthcare
Language:
English
Identifier:
ISSN: 1476-0584
EISSN: 1744-8395
DOI: 10.1586/erv.09.5
PMID: 19348563
Source:
MEDLINE
ProQuest Central
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript